Since the introduction of prophylactic HPV vaccines, both HPV infection rates and cervical cancer rates have subsequently dropped. Yet, cervical cancer remains the fourth most common cancer diagnosis in women globally. As HPV and its role in the development of cervical cancer become better understood, vaccines have emerged as a front runner for improved therapeutic cervical cancer treatment. Recent studies have shown that protein and DNA vaccines may be effectively delivered via the use of several different vectors, while combination therapy with immune checkpoint inhibitors provides even more effective treatment. Further investigation and additional clinical studies into specific vaccine strategies are necessary to determine how effective vaccines are as therapeutic treatment for cervical cancer. This review intends to summarize some of the most promising research on cervical cancer vaccines. Such a study may be helpful for gynecologists to prevent and manage patients with HPV infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861678 | PMC |
| http://dx.doi.org/10.3390/vaccines13020201 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Absence of EpCAM in cervical cancer cells is involved in slug induced epithelial-mesenchymal transition.
Cancer Cell Int
March 2025
Department of Reproductive Medicine, The First Affiliated Hospital of the Medical College, Xi'an Jiaotong University, 76 West Yanta Road, Shaanxi Province, Xi'an, 710061, People's Republic of China.
Tumor-Infiltrating Lymphocyte Therapy: A New Frontier.
Transplant Cell Ther
March 2025
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address:
In recent years, the successful use of tumor-infiltrating lymphocyte (TIL) therapy to treat melanoma not only culminated in a landmark Food and Drug Administration approval, but has also fueled the emergence of a new, rapidly growing field in TIL cellular immunotherapy surrounding novel enhancements in TIL design, refined manufacturing strategies to enrich for more potent TIL populations, as well as numerous clinical trials now investigating TIL therapy in additional solid tumor types beyond melanoma. This review provides a summary of the latest advances in TIL therapy and what lies ahead for the field. The first section explores several solid cancers that demonstrate the greatest potential for future indications of TIL therapy.
View Article and Find Full Text PDFCervical cancer in pregnancy.
Semin Perinatol
March 2025
Lab of Gynecological Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynecology, UZ Leuven, Leuven, Belgium; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:
Cervical cancer is one of the most common and challenging malignancies diagnosed during pregnancy, requiring a complex balance between effective oncological management and pregnancy preservation. This narrative review synthesizes current evidence and clinical experience regarding the management of cervical cancer in pregnant patients. While treatment should generally follow standard protocols for nonpregnant patients, emerging data suggest that pregnancy can often be safely maintained without compromising oncological outcomes.
View Article and Find Full Text PDFSpatial analysis of HPV infection and contextual factors associated with higher HPV prevalence.
Ann Epidemiol
March 2025
NOVA National School of Public Health, NOVA University Lisbon, Av. Padre Cruz, 1600-560, Lisbon, Portugal; NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, NOVA University Lisbon, Av. Padre Cruz, 1600-560, Lisbon, Portugal; Public Health Department, Central Region Health Administration, Av. Dom Afonso Henriques, 141, 3001-553, Coimbra, Portugal; National Institute of Health, Doutor Ricardo Jorge, Av. Padre Cruz, 11, 1649-016, Lisboa, Portugal.
Objectives: To identify areas with high rates of high-risk Papillomavirus (hrHPV) infection and associated contextual factors in the Centre Region of Portugal at the municipality level.
Study Design: We conducted an ecological study in 78 municipalities located in the Central Region of Portugal from March 2019 to December 2022.
Methods: We used data from the cervical cancer screening (CCS) program database after switching to primary HPV testing.
Long Term Results of a Phase II Study of Adjuvant Proton Radiotherapy for Node-Positive Cancer of the Uterus and Cervix: Proton Radiation for Uterine/Cervical Cancer.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
Purpose/objective(s): Patients with node-positive (LN+) uterine or cervical cancer often require post-operative radiation (RT) to the pelvis and para-aortic nodes. A prospective phase II study was conducted to evaluate the efficacy of proton beam RT for LN+ uterine or cervical cancer.
Materials/methods: Patients with IIIC uterine and cervical cancer post hysterectomy and lymphadenectomy were eligible.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!